Project description
A systems biology approach for studying cancer biology
Understanding the complexity of biological systems and phenomena is challenging because they involve many components that interact with each other on multiple levels. Rather than focusing on individual genes, proteins, or pathways in isolation, systems biology takes a holistic approach, considering the system as a network of interconnected components. The EU-funded CanPathPro project aims to develop a systems biology platform for testing cancer signalling hypotheses. The platform will integrate data from a mouse experimental system, next-generation sequencing, and proteomics into a comprehensive systems biology model. The CanPathPro platform is expected to find applications in biotechnology, personalised medicine, and drug development.
Objective
Recent developments in omics technologies demand implementation of systems biology approaches to facilitate analysis and interpretation of the generated complex datasets.This is essential for biotechnological as well as preclinical and clinical applications. In comparison to previous approaches, most cancer relevant studies are confined to pattern recognition or at best modelling of single pathways, rather than the complex pathways and cross-talk determining cancer progression and drug response. Systematic tools that evaluate and validate personalised medicine approaches on a preclinical level are missing; an important prerequisite for translation into clinical practice. The overall objective of CanPathPro is to build and validate a new biotechnological application: a combined experimental and systems biology platform, which will be utilized in testing cancer signaling hypotheses in biomedical research and life sciences. Thus, the proposed project will focus on developing and refining bioinformatic and experimental tools for the evaluation of systems biology modelling predictions. Components comprise a highly controlled mouse experimental system, NGS, a quantitative proteomics based read-out of changes in pathway signalling and an integrative systems biology model for data integration. Testable hypotheses about biological systems will be generated and experimentally validated. The developed system tools will be made available to researchers, SMEs and industry for practical applications. Following this project, a commercial platform for interpretation and analysis of complex omics data and for deriving and testing new hypotheses will be set up by the participating companies and academic partners. CanPathPro will enhance the competitive potential of the SMEs involved expanding in the field of biotechnology, personalised medicine and drug development and also provide new opportunities for other SMEs working in the field of bioinformatics and biomedical applications.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
- medical and health sciences basic medicine pharmacology and pharmacy drug discovery
- medical and health sciences clinical medicine oncology lung cancer
- medical and health sciences health sciences personalized medicine
- natural sciences computer and information sciences artificial intelligence pattern recognition
- natural sciences mathematics applied mathematics mathematical model
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.2.1.4. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology
MAIN PROGRAMME
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
RIA - Research and Innovation action
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-BIOTEC-2014-2015
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
12489 Berlin
Germany
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.